BioCT: 203 470 2720

Connecticut Innovations: 860 563 5851

Greater New Haven has solidified its reputation as a thriving hub for life science, attracting an increasing number of biotech companies. The region is home to nearly half of Connecticut’s biotech firms, benefiting from a robust ecosystem that fosters innovation, research, and commercialization.

Investment in research and development continues to accelerate, with the National Institutes of Health (NIH) allocating 661ドル million to the sector in 2024 - a significant increase from the previous year. This funding has propelled Greater New Haven’s biotech and life science industry forward, reinforcing its reputation as a national leader in cutting-edge medical research. In February 2025, the NIH announced a significant policy change affecting grant fund allocations. The new policy caps indirect cost reimbursements at 15% across all NIH grants, replacing previously negotiated rates that often exceeded this percentage. Indirect costs cover essential expenses such as facility maintenance, administrative support, and utilities, which are crucial for conducting research but are not directly tied to specific projects. This change aims to standardize funding allocations and potentially redirect more funds toward direct research activities. If the policy is implemented, Yale University anticipates a 160ドル million gap.

Yale Ventures is driving significant advancements in science, medicine, and technology through faculty-led spinouts. CREW Carbon secured a 3ドル million agreement with Frontier and raised 5ドル.3 million for carbon capture solutions. In biotech, Allyx Therapeutics has begun Alzheimer’s treatment with its lead compound. BioHaven, in collaboration with Yale, tested a protein degrader in humans for autoimmunity breakthroughs. Halda Therapeutics raised 126ドル million for its solid tumor drugs, and Quantum Circuits garnered 26ドル.5 million to advance quantum computing. Freedom Biosciences received FDA approval for depression treatments, and Ensight-AI earned Breakthrough Device Designation for its medical innovation. Yale Ventures showcases transformative ideas, reinforcing Greater New Haven’s leadership in biotech and deep tech entrepreneurship.

The region plays a crucial role in the life science sector, showcasing a strong and growing presence in bioscience innovation and research. According to the Connecticut Secretary of State’s website, as of January 2025, 215 bioscience and life science firms have been identified within the region. This highlights the area’s significance as a hub for scientific advancement and economic development. These companies contribute to groundbreaking medical research, biotechnology, pharmaceuticals, and healthcare solutions, further solidifying the region’s standing as a key player in the industry.

2025 Report Milestone/Accomplishments

• Medtronic is investing between 750ドル million and 1ドル billion to develop a new campus at its existing site in North Haven. This project will create 300 additional jobs and serve as a physician training facility. The CT Department of Economic and Community Development (DECD) is providing funding to conduct the necessary environmental studies.
• ABCT has relocated to the biotech center at 23 Business Park Dr. in Branford, near Azitra and Quantum-Si. This strategic location encourages growth and start-ups because it is close to Yale and other institutions. Branford has applied for a DECD Grant to enhance the area into a more campus-like setting.
• 101 College Street is a 500,000 sq. ft. medical and laboratory building that opened in 2024. It also includes 30,000 sq. ft. of incubator space.
• Arvinas Inc. has announced its expansion at Science Park, adding 1,500 ft. at 5 Science Park, bringing the total space to 67,500 sq. ft.
• Four life science companies - Cellsbin, EpiTET Therapeutics, NanomediGene, and Oxylus Energy - are expanding in Greater New Haven, enhancing Connecticut's bioscience sector. Together, the companies are investing 16ドル.5 million and will create 31 jobs.
• BioLabs has opened its largest incubator in the United States in New Haven.
• BioMed X, a research institute based in Heidelberg, Germany, has opened a new facility in New Haven. This location is within the Elm City Bioscience Center, a state-of-the-art lab and research hub.
• The first cohort of juniors from New Haven public schools began studies in a new biotechnology lab at 101 College Street as part of the BioPath program, reserved for local residents.
• CURE Rare Disease, a company specializing in rare diseases, relocated from Boston to Woodbridge.
• Branford-based EvolveImmune entered a 65ドル million deal with AbbVie to develop its immunotherapy cancer drug.
• New Haven's Normunity closed a 75ドル million financing round to advance its cancer-fighting drug.
• Connecticut's 100ドル million Innovation Cluster Program has selected finalists, including the "Quantum & Bioscience Cluster" in New Haven. This initiative aims to establish a competitive innovation district utilizing the state's life science infrastructure around YNHHS, Yale University, and CT State Gateway Community College. It plans to add over 550,000 sq. ft. of space, promoting growth in biosciences and quantum technologies while enhancing community through workforce investments and improved transit connections.